Celldex Therapeutics

It took over 3 years and the consult of multiple healthcare providers for Celldex Head of Medical Affairs Sukirti Bagal MD, MPH to receive her diagnosis of both chronic spontaneous urticaria (CSU) and cold urticaria (ColdU). In part two of her story, Suki takes us through her journey to diagnosis and the impact working at Celldex has had on her life. #UDAY2024

When Celldex Head of Medical Affairs Sukirti Bagal MD, MPH works with physicians and patients, she relates to them on a level many other professionals cannot: she, too, lives with chronic spontaneous #urticaria (CSU) and cold urticaria (ColdU) and understands on a personal level just how life-altering this disease can be. In honor of #UDAY2024, Suki shares her journey with urticaria. This is part one of her story.  

Tomorrow is #UDAY2024! Every member of the Celldex team, from research to human resources, is dedicated to advancing our mission of delivering new therapies for inflammatory diseases like #urticaria. We are getting ready to honor the millions affected by urticaria at Celldex tomorrow.

We are gearing up for #UDAY2024 next week. Each year, Urticaria Day aims to raise awareness of chronic #urticaria and advocate for new, improved treatment options for the millions of patients worldwide who live with this condition. We look forward to elevating the voices of team members, patients and healthcare providers next week in recognition of this life-altering disease. Learn more about #UDAY2024 from GA²LEN e.V., the Global Allergy and Asthma European Network.

Today, we are excited to present new data demonstrating sustained and deepening disease efficacy and a well tolerated safety profile over a 52 week treatment period for barzolvolimab in chronic spontaneous #urticaria (CSU). The data were presented at the #EADVCongress by Dr. Martin Metz today. Listen below as Dr. Metz shares what he believes makes these data so exciting for patients. Learn more in the press release here. https://lnkd.in/e49DqfnY

We are excited to introduce our very own #Talent Community! This offers a place for prospective candidates to stay connected to our team so that you can be notified about our career opportunities, company news and events we will be attending. Upon signing up, you will be enrolled to receive Celldex updates and the exciting work we are doing to improve the lives of patients with severe inflammatory, allergic, autoimmune, and other devastating diseases. Sign up is quick and easy: simply click the link below to submit your resume or join by email. 

Dr. Marcus Maurer was a champion for urticaria research and a deeply dedicated advocate for new treatments to improve the lives of patients. It is with heavy hearts we share a statement from CEO Anthony Marucci on the news of his passing.

As the summer games come to a close, we channelled our inner athletes in our Fall River office for some friendly competition! Team members battled it out in the water balloon pass, "gown up" race and "potato between the leg" race. Next stop, Paris! 

KIT expression is critical to the activity and survival of #mastcells. Celldex's approach to developing antibody therapeutics has been built on the inhibition of KIT to shut down harmful mast cells as a means to treat mast cell driven diseases. Tibor Keler, Ph.D. shares more on why we believe this could be transformative for patients living with #inflammatory diseases in the final episode of Talking with Tibor.

Mast cells play a key role in #allergy and #inflammatory diseases, and are responsible for many harmful symptoms that patients with these diseases experience. In part 2 of our Talking with Tibor series, Dr. Tibor Keler dives into what a #mastcell is, and where they get their infamous reputation.